The Medical Letter on Drugs and Therapeutics
Golimumab (Simponi) for Inflammatory Arthritis
The full article is available to subscribers Subscriber Login   
Revised 7/22/09: In the first sentence "humanized" was changed to "human." In Table 1, the source for certolizumab (Cimzia) was changed to "humanized" and the price should have been $1,341.68 (not $3,136.40).

Golimumab (Simponi – Centocor), a fully human anti-tumor necrosis factor (TNF)-α antibody, has been approved by the FDA for the treatment of: (1) moderate to severe active rheumatoid arthritis (RA) in combination with methotrexate; (2) active psoriatic arthritis (PsA) alone or in combination with methotrexate; and (3) active ankylosing spondylitis (AS). Treatment of rheumatoid arthritis was recently reviewed in Treatment Guidelines from The Medical Letter.1

MECHANISM OF ACTION — TNF-α is a pro-inflammatory cytokine that is central in the pathogenesis of many systemic inflammatory disorders. Four recombinant agents that inhibit TNF-α are already available (see Table 1). Like infliximab, certolizumab and adalimumab, golimumab acts by targeting and neutralizing both circulating and membrane-bound TNF-α. Etanercept inhibits only soluble ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Immediate Online access to current issue and archives from 1988 to the present
  • Mobile access to our mobile site and free apps for iOS, Android and Kindle
  • FREE online per issue CME/CE
Free trial offer
3 Free Issues of The Medical Letter on Drugs and Therapeutics mailed to your home or office PLUS online access.
Try a Free Trial Subscription
Purchase this article:
Title: Golimumab (Simponi) for Inflammatory Arthritis
Article code: 1316b
 Electronic, downloadable article - $25